

**LEGISLATIVE SERVICES AGENCY  
OFFICE OF FISCAL AND MANAGEMENT ANALYSIS**

200 W. Washington, Suite 301  
Indianapolis, IN 46204  
(317) 233-0696  
<http://www.in.gov/legislative>

**FISCAL IMPACT STATEMENT**

**LS 7359**

**BILL NUMBER:** HB 1315

**NOTE PREPARED:** Feb 4, 2013

**BILL AMENDED:** Jan 31, 2013

**SUBJECT:** Biosimilar Biological Products.

**FIRST AUTHOR:** Rep. Clere

**FIRST SPONSOR:** Sen. Patricia Miller

**BILL STATUS:** As Passed House

**FUNDS AFFECTED:** X **GENERAL  
DEDICATED  
FEDERAL**

**IMPACT:** State

**Summary of Legislation:** This bill provides that a biological product that is substituted under the biosimilar biological products requirements is not subject to the generic drug substitution requirements. The bill allows a pharmacist to substitute a biosimilar product for a prescribed biological product if certain conditions are met.

The bill requires the Board of Pharmacy to maintain an Internet web site that lists the biosimilar biological products that are determined to be interchangeable.

The bill allows the Board of Pharmacy to adopt rules.

It also provides that a written or electronic prescription for a biological product must comply with the existing prescription form requirements.

**Effective Date:** July 1, 2013.

**Explanation of State Expenditures:** The Indiana Professional Licensing Agency (IPLA) reports that the Board of Pharmacy Internet web page requirement can be accomplished within the level of resources currently available to the agency.

**Explanation of State Revenues:**

**Explanation of Local Expenditures:**

**Explanation of Local Revenues:**

**State Agencies Affected:** IPLA, Board of Pharmacy.

**Local Agencies Affected:**

**Information Sources:** IPLA.

**Fiscal Analyst:** Kathy Norris, 317-234-1360.